2019 Volumes

From the Desk of the Editor: Volume 5, Issue 4

Dear Colleagues, As the 2020 pandemic has altered our behavioral, economic, educational policies, and numerous other career and life events worldwide, SARS-CoV-2 has also impacted global healthcare and patient outcomes. Fortunately, and not unexpectedly, frontline and advanced line healthcare workers, researchers, and scientists have never ceased the tradition of tireless sacrifice and dedication to advancing patient care. Assuredly we have reviewed and read exceptional cancer care advancements in 2020, including innovative efforts for delivering care via ambulatory processes or through virtual technologies while prioritizing our most vulnerable patient populations. Fortunately, numerous diagnostic and therapeutic advancements in 2020 have occurred in Genitourinary Oncology.

While safeguarding both patients and the healthcare team from unnecessary risk of SARS-CoV-2, telehealth technology and its widespread adoption among healthcare practitioners and patients have allowed for innovative patient care strategies. Virtual education has also persevered and improved during this year of in-person and travel adversity.

READ MORE PREVIOUS ARTICLES

Alicia Morgans, MD, MPH Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts. She is a clinician and physician investigator specializing in investigating complications of systemic therapy for prostate cancer survivors. She has expertise in clinical trials and patient-reported outcome measures, and as well as incorporating patient preferences and beliefs into clinical decision making.